ALESSANDRO ANDRIANI

Dr. ALESSANDRO ANDRIANI


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2006 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
AAALESSANDRO ANDRIANI
ALESSANDRO ANDRIANI
AZAngelo Zullo
Angelo Zullo
FRFrancesco Di Raimondo
Francesco Di Raimondo
CPC. Patti
C. Patti
LTL. Tedeschi
L. Tedeschi
AZAngelo Zullo
Angelo Zullo

1 July 2009 in Digestive and Liver Disease
Verified
Journal Article
Closed access
AAALESSANDRO ANDRIANI
ALESSANDRO ANDRIANI
AMA. Miedico
A. Miedico
LTL. Tedeschi
L. Tedeschi
CPC. Patti
C. Patti
FRFrancesco Di Raimondo
Francesco Di Raimondo
AZAngelo Zullo
Angelo Zullo

7 January 2016 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
AAALESSANDRO ANDRIANI
ALESSANDRO ANDRIANI
RLRoberto Latagliata
Roberto Latagliata
BABarbara Anaclerico
Barbara Anaclerico
ASAntonio Spadea
Antonio Spadea
ARAngela Rago
Angela Rago
Francesca PalandriFrancesca Palandri
Francesca Palandri
Spleen enlargement, present in 10–20% of Essential Thrombocythemia (ET) patients at diagnosis, is a feature clinically easy to assess, confirmable by echography with a very low chance of misinterpretation. Nonetheless, the clinical and prognostic role of splenomegaly has been seldom evaluated. From 1979 to 2013, 1297 ET patients retrospectively collected in the database of the Lazio Cooperative Group and Bologna University Hospital were evaluable for spleen enlargement at diagnosis and included in the analysis. On the whole, spleen was enlarged in 172/1297 (13.0%) patients; in most cases (94.8%) splenomegaly was mild (≤5 cm). Patients with splenomegaly were younger, predominantly male, presented higher platelet count and JAK2V617F allele burden and had a lower incidence of concomitant cardiovascular risk factors. At least one thrombotic event during follow‐up occurred in 97/1,125 (8.6%) patients without spleen enlargement compared to 27/172 (15.7%) patients with spleen enlargement (P = 0.003). Despite comparable use of cytoreductive/antiplatelet therapies in the two groups, the cumulative risk of thrombosis at 5 years was significantly higher in patients with baseline splenomegaly (9.8% versus 4.4% in patients without splenomegaly, P = 0.012). In multivariate analysis exploring risk factors for thrombosis, splenomegaly retained its negative prognostic role, together with previous thrombosis, leucocyte count and male gender. Baseline splenomegaly seems to be an independent additional risk factor for thrombosis in nonstrictly WHO‐defined ET patients. This data could be useful in the real‐life clinical management of these patients. Am. J. Hematol. 91:318–321, 2016.

1 August 2015 in Leukemia Research
Verified
Journal Article
Closed access
AAALESSANDRO ANDRIANI
ALESSANDRO ANDRIANI
MMMarco Montanaro
Marco Montanaro
MVMaria Teresa Voso
Maria Teresa Voso
NVNicoletta Villivà
Nicoletta Villivà
FCFabrizio Ciccone
Fabrizio Ciccone
RLRoberto Latagliata
Roberto Latagliata

21 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Francesca PalandriFrancesca Palandri
Francesca Palandri
ERElena Rossi
Elena Rossi
GAGiuseppe Auteri
Giuseppe Auteri
Massimo BrecciaMassimo Breccia
Massimo Breccia
SPSimona Paglia
Simona Paglia
Valerio De StefanoValerio De Stefano
Valerio De Stefano
In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), the predictors of response, and patients’ triggers for switching to ruxolitinib are uncertain. In a real-world analysis, we evaluated the predictors of response, their impact on the clinical outcomes of CR to HU, and the correlations between partial or no response (PR/NR) and a patient switching to ruxolitinib. Among 563 PV patients receiving HU for ≥12 months, 166 (29.5%) achieved CR, 264 achieved PR, and 133 achieved NR. In a multivariate analysis, the absence of splenomegaly (p = 0.03), pruritus (p = 0.002), and a median HU dose of ≥1 g/day (p < 0.001) remained associated with CR. Adverse events were more frequent with a median HU dose of ≥1 g/day. Overall, 283 PR/NR patients (71.3%) continued HU, and 114 switched to ruxolitinib. In the 449 patients receiving only HU, rates of thrombosis, hemorrhages, progression, and overall survival were comparable among the CR, PR, and NR groups. Many PV patients received underdosed HU, leading to lower CR and toxicity rates. In addition, many patients continued HU despite a PR/NR; however, splenomegaly and other symptoms were the main drivers of an early switch. Better HU management, standardization of the criteria for and timing of responses to HU, and adequate intervention in poor responders should be advised.

3 May 2019 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
AAALESSANDRO ANDRIANI
ALESSANDRO ANDRIANI
Elena Maria ElliElena Maria Elli
Elena Maria Elli
GTGiulio Trapè
Giulio Trapè
NVNicoletta Villivà
Nicoletta Villivà
LFLuana Fianchi
Luana Fianchi
RLRoberto Latagliata
Roberto Latagliata